What is Merus BV (MRUS) stock price today?

Merus BV (MRUS) currently trades at $90.00 per share. The stock has a market capitalization of $6.83B and a P/E ratio of —x.

Is MRUS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Merus BV has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 0.85.

What is Merus BV's revenue and earnings?

Merus BV has trailing twelve-month (TTM) revenue of $56.61M with profit margins of 0.00%. Earnings per share (EPS) is $-5.28.

Is Merus BV financially healthy?

Merus BV's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 0.85 places it in the distress.

MRUS

Merus BV

NASDAQ: MRUS · HEALTHCARE · BIOTECHNOLOGY

$90.00

+0.00% today

Updated 2025-12-30

Market cap

$6.83B

P/E ratio

—

P/S ratio

120.59x

EPS (TTM)

$-5.28

Dividend yield

—

52W range

$33 – $97

Volume

1.3M

Market cap

$6.83B

P/E ratio

—

P/S ratio

120.59x

EPS (TTM)

$-5.28

Dividend yield

—

52W range

$33 – $97

Volume

1.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.3

Growth

5.3

Quality

C+

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$97.00

+7.78%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy14 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 0.85 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-85.25M

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$43.15M	$38.84M	$39.81M	$34.88M	$56.61M
Net income	$-58.70M	$-122.52M	$-140.34M	$-207.85M	$-81.55M
EPS	—	—	—	—	$-5.28
Free cash flow	$-60.50M	$-157.54M	$-146.19M	$-187.50M	$-85.25M
Profit margin	-136.06%	-315.48%	-352.56%	-595.93%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MRUS	$6.83B	24	3.3	2.5	5.0	5.3	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Merus BV trades at $90.00. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.85, it sits in the distress. TTM revenue stands at $56.61M.

Frequently asked questions

What is Merus BV's stock price?

Merus BV (MRUS) trades at $90.00.

Is Merus BV overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Merus BV (MRUS)?

The analyst target price is $97.00, representing +7.8% upside from the current price of $90.00.

What is Merus BV's revenue?

TTM revenue is $56.61M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

0.85 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio120.59x

ROE-0.52%

Beta1.06

50D MA$95.41

200D MA$69.34

Shares out0.08B

Float0.07B

Short ratio—

Avg volume1.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MRUS vs LLY →MRUS vs JNJ →MRUS vs ABBV →Stock screener →